Cargando…
Microfluidic hemophilia models using blood from healthy donors
BACKGROUND: Microfluidic clotting assays permit drug action studies for hemophilia therapeutics under flow. However, limited availability of patient samples and Inter‐donor variability limit the application of such assays, especially with many patients on prophylaxis. OBJECTIVE: To develop approache...
Autores principales: | Yu, Xinren, Panckeri, Karen A., Ivanciu, Lacramioara, Camire, Rodney M., Coxon, Carmen H., Cuker, Adam, Diamond, Scott L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971334/ https://www.ncbi.nlm.nih.gov/pubmed/31989085 http://dx.doi.org/10.1002/rth2.12286 |
Ejemplares similares
-
Correction of the coagulation defect in hemophilia using a factor Xa variant with novel engineered protease function
por: Ivanciu, Lacramioara, et al.
Publicado: (2011) -
Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015) -
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
por: Hui, Daniel J, et al.
Publicado: (2015) -
Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study
por: Cheng, Ji, et al.
Publicado: (2016) -
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)